EP2929041A4 - PENTAENOIC ACID COMPOSITIONS OF OMEGA-3 AND ASSOCIATED METHODS OF USE - Google Patents

PENTAENOIC ACID COMPOSITIONS OF OMEGA-3 AND ASSOCIATED METHODS OF USE

Info

Publication number
EP2929041A4
EP2929041A4 EP13861394.8A EP13861394A EP2929041A4 EP 2929041 A4 EP2929041 A4 EP 2929041A4 EP 13861394 A EP13861394 A EP 13861394A EP 2929041 A4 EP2929041 A4 EP 2929041A4
Authority
EP
European Patent Office
Prior art keywords
omega
methods
acid compositions
pentaenoic acid
pentaenoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13861394.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2929041A1 (en
Inventor
George Bobotas
Abdel Aziz Fawzy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Priority to EP21170003.4A priority Critical patent/EP3888646A1/en
Publication of EP2929041A1 publication Critical patent/EP2929041A1/en
Publication of EP2929041A4 publication Critical patent/EP2929041A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23DEDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/06Preservation of finished products
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23DEDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00Other edible oils or fats, e.g. shortenings, cooking oils
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11BPRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B5/00Preserving by using additives, e.g. anti-oxidants
    • C11B5/0007Organic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
EP13861394.8A 2012-12-06 2013-12-06 PENTAENOIC ACID COMPOSITIONS OF OMEGA-3 AND ASSOCIATED METHODS OF USE Withdrawn EP2929041A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21170003.4A EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734331P 2012-12-06 2012-12-06
US201361780948P 2013-03-13 2013-03-13
PCT/US2013/073701 WO2014089501A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP21170003.4A Division EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Publications (2)

Publication Number Publication Date
EP2929041A1 EP2929041A1 (en) 2015-10-14
EP2929041A4 true EP2929041A4 (en) 2016-06-08

Family

ID=50884050

Family Applications (3)

Application Number Title Priority Date Filing Date
EP13861305.4A Withdrawn EP2928462A4 (en) 2012-12-06 2013-12-06 METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID
EP21170003.4A Withdrawn EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use
EP13861394.8A Withdrawn EP2929041A4 (en) 2012-12-06 2013-12-06 PENTAENOIC ACID COMPOSITIONS OF OMEGA-3 AND ASSOCIATED METHODS OF USE

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP13861305.4A Withdrawn EP2928462A4 (en) 2012-12-06 2013-12-06 METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID
EP21170003.4A Withdrawn EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use

Country Status (9)

Country Link
EP (3) EP2928462A4 (ko)
JP (4) JP2016501249A (ko)
KR (3) KR20150103009A (ko)
CN (4) CN104937103A (ko)
AU (7) AU2013354969A1 (ko)
CA (2) CA2894366A1 (ko)
IN (2) IN2015MU01505A (ko)
MX (2) MX2015007082A (ko)
WO (2) WO2014089511A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101568665B1 (ko) 2015-07-21 2015-11-12 디와이오토 주식회사 모터의 맥동 전류를 증가시키는 브러시 구조
EP3475704A1 (en) * 2016-06-28 2019-05-01 Nestec S.A. Biomarkers of blood-brain barrier dysfunction
JP2018168139A (ja) * 2016-10-21 2018-11-01 マルハニチロ株式会社 n−3系不飽和脂肪酸を含む中性脂肪値の低減または上昇抑制用の組成物、並びに該組成物の製造におけるn−3系不飽和脂肪酸の使用
JP7099821B2 (ja) * 2017-12-20 2022-07-12 ポッカサッポロフード&ビバレッジ株式会社 Pcsk9阻害剤及びコレステロール代謝改善用食品組成物
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2002125618A (ja) * 2000-10-30 2002-05-08 Katsuyuki Wakatsuki 健康食品
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
AU2007270135B9 (en) * 2006-07-05 2013-06-27 Fermentalg Production of ultrapure EPA and polar lipids from largely heterotrophic culture
WO2010103402A1 (en) * 2009-03-09 2010-09-16 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form and a surfactant, and methods and uses thereof
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
BRPI1011876B1 (pt) * 2009-04-29 2020-03-31 Amarin Pharma, Inc. Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular
CN102625847A (zh) * 2009-06-15 2012-08-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
EP2675442A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
EP2675445A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014089501A1 *

Also Published As

Publication number Publication date
CN112107570A (zh) 2020-12-22
WO2014089511A3 (en) 2014-07-31
CN104937103A (zh) 2015-09-23
AU2021201865A1 (en) 2021-04-22
JP2016501249A (ja) 2016-01-18
MX2015007085A (es) 2016-01-12
KR20150103009A (ko) 2015-09-09
AU2019216634A1 (en) 2019-09-05
EP2928462A2 (en) 2015-10-14
EP2929041A1 (en) 2015-10-14
AU2013354979A1 (en) 2015-06-11
AU2017232203A1 (en) 2017-10-12
CA2894366A1 (en) 2014-06-12
AU2013354969A1 (en) 2015-06-11
MX2015007082A (es) 2016-01-12
AU2018229440A1 (en) 2018-10-04
IN2015DE05009A (ko) 2015-12-18
WO2014089511A2 (en) 2014-06-12
IN2015MU01505A (ko) 2016-05-27
JP2019172697A (ja) 2019-10-10
KR20210059779A (ko) 2021-05-25
JP2021120407A (ja) 2021-08-19
CN104902888A (zh) 2015-09-09
WO2014089501A1 (en) 2014-06-12
KR20150103671A (ko) 2015-09-11
EP3888646A1 (en) 2021-10-06
CA2894183A1 (en) 2014-06-12
JP6881893B2 (ja) 2021-06-02
CN113274378A (zh) 2021-08-20
EP2928462A4 (en) 2016-06-01
AU2020203658A1 (en) 2020-06-25
JP2016501248A (ja) 2016-01-18

Similar Documents

Publication Publication Date Title
EP2861227A4 (en) OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
HK1212701A1 (zh) 恩雜魯胺製劑
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
ZA201508059B (en) Compositions and methods of use of phorbol esters
EP3735963C0 (en) SELF-EMULSIFYING COMPOSITION OF OMEGA-3 FATTY ACIDS
SG11201404930SA (en) Post-cmp removal using compositions and method of use
SG10201800243XA (en) SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
EP2827868A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING FATTY ACID ESTERS
EP2917314A4 (en) OLIGOMERATZUSAMMENSETZUNG
EP2895586A4 (en) DETERGENT COMPOSITION COMPRISING PHOSPHINOSUCCINIC ACID ADDITION PRODUCTS AND METHODS OF USE
EP2906041A4 (en) COMPOSITIONS AND METHODS OF USING INAPPETENCE COMPOUND
EP2968246A4 (en) OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE
IL245588A0 (en) Solid compositions of triglycerides and their use
EP2929041A4 (en) PENTAENOIC ACID COMPOSITIONS OF OMEGA-3 AND ASSOCIATED METHODS OF USE
EP2852370A4 (en) FLASH-CONTAINING COMPOSITIONS AND METHODS OF USE
EP2809337A4 (en) EFFECTORS OF SS-ARRESTINE AND COMPOSITIONS AND METHODS OF USE THEREOF
EP2751071A4 (en) Fatty Acid Amide, Compositions Thereof and Method of Use Therefor
HK1212164A1 (en) Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof ---
EP2859071A4 (en) CHEMICAL COMPOSITIONS AND METHODS OF USE
IL239623A0 (en) Methods and preparations for administering oxybutynin
EP2841164A4 (en) COMPOSITIONS AND USE PROCEDURES FOR THE SKIN
GB201208974D0 (en) Improvements in the manufacture of fatty acids
AU2012904573A0 (en) Nutritional Compositions and Methods of Manufacture

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/40 20060101ALI20160429BHEP

Ipc: A61K 31/202 20060101ALI20160429BHEP

Ipc: A61K 31/225 20060101AFI20160429BHEP

Ipc: A23D 9/00 20060101ALI20160429BHEP

Ipc: C11B 5/00 20060101ALI20160429BHEP

Ipc: A61K 9/48 20060101ALI20160429BHEP

Ipc: A23D 9/06 20060101ALI20160429BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220701